Evotec Provides Guidance Update

Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just - Evotec Biologics with mid double-digit revenue growth versus strong comparable basisAdjusted EBITDA impacted by high fixed cost base in Shared R&D and …
Jetzt den vollständigen Artikel lesen